- Home
- ARMP vs JRVR Comparison
ARMP vs JRVR Comparison
Compare ARMP & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARMP | JRVR |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 209.9M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ARMP | JRVR |
|---|---|---|
| Price | $5.38 | $3.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $15.00 | $7.33 |
| AVG Volume (30 Days) | 82.8K | ★ 210.1K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.64% |
| EPS Growth | N/A | ★ 125.82 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $687,614,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.86 | $3.76 |
| 52 Week High | $14.98 | $7.20 |
Technical Indicators
Market Signals| Indicator | ARMP | JRVR |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 33.86 |
| Support Level | $5.12 | $3.82 |
| Resistance Level | $5.63 | $4.26 |
| Average True Range (ATR) | 0.44 | 0.10 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 48.63 | 2.67 |
Price Performance
Historical ComparisonAbout ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
About JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.